{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:22:03Z","timestamp":1791908523777,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.jaad.2010.05.033","type":"journal-article","created":{"date-parts":[[2011,4,24]],"date-time":"2011-04-24T17:09:53Z","timestamp":1303664993000},"page":"546-551","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":116,"title":["Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients"],"prefix":"10.1016","volume":"65","author":[{"given":"Namita","family":"Kothary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida-Lina","family":"Diak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Brinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shewit","family":"Bezabeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Avigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Dal Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2010.05.033_bib1","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ncl.2008.03.007","article-title":"Progressive multifocal leukoencephalopathy","volume":"26","author":"Weber","year":"2008","journal-title":"Neurol Clin"},{"key":"10.1016\/j.jaad.2010.05.033_bib2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1128\/CMR.5.1.49","article-title":"Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain","volume":"5","author":"Major","year":"1992","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jaad.2010.05.033_bib3","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJMoa0810257","article-title":"Treatment of progressive multifocal leukoencephalopathy associated with natalizumab","volume":"361","author":"Wenning","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2010.05.033_bib4","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa0810316","article-title":"Progressive multifocal leukoencephalopathy after natalizumab monotherapy","volume":"361","author":"Linda","year":"2009","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.jaad.2010.05.033_bib5","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1086\/344280","article-title":"Traffic of JC virus from sites of initial infection to the brain: The path to progressive multifocal leukoencephalopathy","volume":"186","author":"Sabath","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaad.2010.05.033_bib6","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1212\/01.wnl.0000233918.21986.9c","article-title":"Characteristics and antecedents of progressive multifocal leukoencephalopathy in an insured population","volume":"67","author":"Eng","year":"2006","journal-title":"Neurol"},{"key":"10.1016\/j.jaad.2010.05.033_bib7","series-title":"Campath (alemtuzumab) Prescribing Information","year":"2009"},{"key":"10.1016\/j.jaad.2010.05.033_bib8","series-title":"Arranon (nelarabine) Prescribing Information","year":"2006"},{"key":"10.1016\/j.jaad.2010.05.033_bib9","series-title":"Fortovase (saquinavir) Prescribing Information","year":"2003"},{"key":"10.1016\/j.jaad.2010.05.033_bib10","series-title":"Invirase (saquinavir mesylate) Prescribing Information","year":"2007"},{"key":"10.1016\/j.jaad.2010.05.033_bib11","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1056\/NEJMoa0904267","article-title":"Asymptomatic reactivation of JC virus in patients treated with natalizumab","volume":"361","author":"Chen","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2010.05.033_bib12","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1002\/art.24966","article-title":"Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases","volume":"60","author":"Molloy","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2010.05.033_bib13","series-title":"Raptiva (efalizumab) Prescribing Information","year":"2009"},{"key":"10.1016\/j.jaad.2010.05.033_bib14","unstructured":"Food and Drug Administration. FDA Approval Letter for BLA 125075 (efalizumab, Raptiva) dated October 27, 2003. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2003\/125075-0ltr.pdf. Accessed Sept 11, 2009."},{"key":"10.1016\/j.jaad.2010.05.033_bib15","series-title":"Raptiva (efalizumab) Prescribing Information","year":"2008"},{"key":"10.1016\/j.jaad.2010.05.033_bib16","unstructured":"Food and Drug Administration. FDA statement on the voluntary withdrawal of Raptiva from the U.S. market. Available at: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm149561.htm. Accessed June 23, 2009."},{"key":"10.1016\/j.jaad.2010.05.033_bib17","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.05.033_bib18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaad.2005.03.050","article-title":"Decision points for the initiation of systemic treatment for psoriasis","volume":"53","author":"Feldman","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.05.033_bib19","series-title":"Humira (adalimumab) Prescribing Information","year":"2009"},{"key":"10.1016\/j.jaad.2010.05.033_bib20","series-title":"Amevive (alefacept) Prescribing Information","year":"2009"},{"key":"10.1016\/j.jaad.2010.05.033_bib21","series-title":"Enbrel (etanercept) Prescribing Information","year":"2009"},{"key":"10.1016\/j.jaad.2010.05.033_bib22","series-title":"Remicade (infliximab) Prescribing Information","year":"2009"},{"key":"10.1016\/j.jaad.2010.05.033_bib23","series-title":"Stelara (ustekinumab) Prescribing Information","year":"2009"},{"key":"10.1016\/j.jaad.2010.05.033_bib24","unstructured":"Food and Drug Administration. Adverse event reporting system (AERS). Available at: http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/default.htm. Accessed June 23, 2009."},{"key":"10.1016\/j.jaad.2010.05.033_bib25","unstructured":"Code of Federal Regulations, Title 21, Volume 5, revised April 1, 2009. 21 CFR 314.80: Postmarketing reporting of adverse drug experiences. Available at: http:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?fr=314.80. Accessed Oct 14, 2009."},{"key":"10.1016\/j.jaad.2010.05.033_bib26","unstructured":"MedDra MSSO and Northrop Grumman. MedDRA. Available at: http:\/\/www.meddramsso.com. Accessed Oct 14, 2009."},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2010.05.033_bib27","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/13550280390195298","article-title":"The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology","volume":"9","author":"Cinque","year":"2003","journal-title":"J Neurovirol"},{"key":"10.1016\/j.jaad.2010.05.033_bib28","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0895-4356(92)90088-5","article-title":"Power and weakness of spontaneous reporting: a probabilistic approach","volume":"45","author":"Tubert","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jaad.2010.05.033_bib29","unstructured":"Centers for Disease Control and Prevention. Laboratory Procedure Manual: CD4+ T-lymphocytes and CD8 T cells. Available at: http:\/\/www.cdc.gov\/Nchs\/data\/nhanes\/nhanes_03_04\/l03_c_met_CD4%2B_CD8%2B.pdf. Accessed Oct 27, 2009."},{"key":"10.1016\/j.jaad.2010.05.033_bib30","unstructured":"Genentech, Inc. Genentech statement to Healthcare Professionals: Important safety information. Available at: http:\/\/www.gene.com\/gene\/products\/information\/pdf\/raptiva_dhcp.pdf. Accessed June 20, 2009."},{"key":"10.1016\/j.jaad.2010.05.033_bib31","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/jnnp.2009.187666","article-title":"Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression","volume":"81","author":"Gheuens","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962210006262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962210006262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:22:07Z","timestamp":1759270927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962210006262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0190962210006262"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2010.05.033","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2010.05.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}